Copyright
©The Author(s) 2026. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Orthop. Feb 18, 2026; 17(2): 112757
Published online Feb 18, 2026. doi: 10.5312/wjo.v17.i2.112757
Published online Feb 18, 2026. doi: 10.5312/wjo.v17.i2.112757
Weight-adjusted low molecular weight heparin with surgery morning dose administration: Impact on hip hemiarthroplasty early infections
Ahmed M Nageeb Mahmoud, Juan Bernate, Daniel S Horwitz, Department of Orthopedic Surgery, Geisinger Medical Center, Danville, PA 17822, United States
Ahmed M Nageeb Mahmoud, Department of Orthopedic Surgery, Faculty of Medicine, Ain Shams University, Cairo 11591, Egypt
Hemil Hasmukh Maniar, Department of Orthopedic Surgery, Lawrence Memorial Hospital, Lawrence, KS 66044, United States
Author contributions: Nageeb Mahmoud AM and Horwitz DS contributed to the conceptualization and methodology; Nageeb Mahmoud AM, Maniar HH, and Bernate J contributed to the investigation; Nageeb Mahmoud AM, Maniar HH, and Bernate J participated in the data curation; Nageeb Mahmoud AM wrote the original draft; Nageeb Mahmoud AM, Horwitz DS, and Maniar HH reviewed and edited the manuscript; Horwitz DS and Maniar HH contributed to the supervision; All authors have read and agreed to the published version of the manuscript.
Institutional review board statement: The study was reviewed and approved by the Geisinger Institutional Review Board (Approval No. 2023-01156).
Informed consent statement: Patients were not required to give informed consent to the study because the retrospective analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: The data can be shared upon a request from the corresponding author after a data use agreement.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ahmed M Nageeb Mahmoud, Academic Fellow, Assistant Professor, Senior Research Fellow, Department of Orthopedic Surgery, Geisinger Medical Center, 100 N Academy Ave, Danville, PA 17822, United States. Ahmednageeb2011@gmail.com;
Received: August 6, 2025
Revised: September 9, 2025
Accepted: November 25, 2025
Published online: February 18, 2026
Processing time: 183 Days and 14.1 Hours
Revised: September 9, 2025
Accepted: November 25, 2025
Published online: February 18, 2026
Processing time: 183 Days and 14.1 Hours
Core Tip
Core Tip: This study evaluated whether switching to a weight-based low-molecular-weight heparin (LMWH) regimen with morning-of-surgery dosing affects early prosthetic joint infection (PJI) rates in patients with hip hemiarthroplasty. No statistically significant difference in early PJI rates was observed between the standard and modified LMWH protocols. These findings suggest that LMWH dose escalation does not significantly impact early PJI risk, although larger studies are warranted.